menu
    • menu
    [{"orgOrder":0,"company":"Andromaco","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHILE","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Meloxicam","moa":"Cyclooxygenase-2","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Andromaco","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Andromaco \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Andromaco \/ Undisclosed"},{"orgOrder":0,"company":"National Taiwan University Hospital","sponsor":"TCM Biotech International Corp.","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"TAIWAN","productType":"Miscellaneous","year":"2022","type":"Inapplicable","leadProduct":"Pentosan Polysulfate Sodium","moa":"FGFR-2\/FGFR-3","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"National Taiwan University Hospital","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"National Taiwan University Hospital \/ TCM Biotech International Corp.","highestDevelopmentStatusID":"9","companyTruncated":"National Taiwan University Hospital \/ TCM Biotech International Corp."},{"orgOrder":0,"company":"Copenhagen University Hospital at Herlev","sponsor":"Rigshospitalet | Copenhagen University Hospital, Hvidovre | Hillerod Hospital, Denmark | Blood Bank of the Danish Capital Region | Unit for Monitoring of Good Clinical Practice, Copenhagen University | Danish Council for Independent Research | Herlev Hosp","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"DENMARK","productType":"Protein","year":"2011","type":"Inapplicable","leadProduct":"Fibrinogen","moa":"Fibrinogen","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Copenhagen University Hospital at Herlev","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Copenhagen University Hospital at Herlev \/ Rigshospitalet | Copenhagen University Hospital, Hvidovre | Hillerod Hospital, Denmark | Blood Bank of the Danish Capital Region | Unit for Monitoring of Good Clinical Practice, Copenhagen University | Danish Council for Independent Research | Herlev Hosp","highestDevelopmentStatusID":"9","companyTruncated":"Copenhagen University Hospital at Herlev \/ Rigshospitalet | Copenhagen University Hospital, Hvidovre | Hillerod Hospital, Denmark | Blood Bank of the Danish Capital Region | Unit for Monitoring of Good Clinical Practice, Copenhagen University | Danish Council for Independent Research | Herlev Hosp"},{"orgOrder":0,"company":"Pacific Centre for Reproductive Medicine","sponsor":"EMD Serono","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CANADA","productType":"Hormone","year":"2012","type":"Inapplicable","leadProduct":"Somatropin","moa":"Growth hormone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Pacific Centre for Reproductive Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Injection","sponsorNew":"Pacific Centre for Reproductive Medicine \/ EMD Serono","highestDevelopmentStatusID":"9","companyTruncated":"Pacific Centre for Reproductive Medicine \/ EMD Serono"},{"orgOrder":0,"company":"Centre For International Health","sponsor":"Tribhuvan University Teaching Hospital, Institute of Medicine | NORCE Norwegian Research Centre AS | Sykehuset Innlandet HF","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NORWAY","productType":"Vitamins\/Minerals\/Inorganic Salts","year":"2017","type":"Inapplicable","leadProduct":"Vitamin B12","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Centre For International Health","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Centre For International Health \/ Tribhuvan University Teaching Hospital, Institute of Medicine | NORCE Norwegian Research Centre AS | Sykehuset Innlandet HF","highestDevelopmentStatusID":"9","companyTruncated":"Centre For International Health \/ Tribhuvan University Teaching Hospital, Institute of Medicine | NORCE Norwegian Research Centre AS | Sykehuset Innlandet HF"},{"orgOrder":0,"company":"Academisch Medisch Centrum - Universiteit van Amsterdam","sponsor":"ZonMw","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"NETHERLANDS","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Sildenafil Citrate","moa":"Phosphodiesterase 5A","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Academisch Medisch Centrum - Universiteit van Amsterdam","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw","highestDevelopmentStatusID":"9","companyTruncated":"Academisch Medisch Centrum - Universiteit van Amsterdam \/ ZonMw"},{"orgOrder":0,"company":"Obstetrix Medical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2013","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Obstetrix Medical Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Gel","sponsorNew":"Obstetrix Medical Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Obstetrix Medical Group \/ Undisclosed"},{"orgOrder":0,"company":"Eastern Virginia Medical School","sponsor":"Watson Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Hormone","year":"2018","type":"Inapplicable","leadProduct":"Progesterone","moa":"Progesterone receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Eastern Virginia Medical School","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Suppository","sponsorNew":"Eastern Virginia Medical School \/ Watson Pharmaceuticals","highestDevelopmentStatusID":"9","companyTruncated":"Eastern Virginia Medical School \/ Watson Pharmaceuticals"},{"orgOrder":0,"company":"Dexa Medica","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"INDONESIA","productType":"Undisclosed","year":"2013","type":"Inapplicable","leadProduct":"DLBS1442","moa":"Pro-inflammatory cytokine","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Dexa Medica","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Dexa Medica \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Dexa Medica \/ Undisclosed"},{"orgOrder":0,"company":"Gynuity Health Projects","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2014","type":"Inapplicable","leadProduct":"Misoprostol","moa":"Prostanoid EP3 receptor","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Gynuity Health Projects","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Gynuity Health Projects \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Gynuity Health Projects \/ Undisclosed"},{"orgOrder":0,"company":"AMAG Pharmaceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Miscellaneous","year":"2017","type":"Inapplicable","leadProduct":"Digoxin","moa":"Sodium\/potassium-transporting ATPase","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"AMAG Pharmaceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Infusion","sponsorNew":"AMAG Pharmaceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"AMAG Pharmaceuticals \/ Undisclosed"},{"orgOrder":0,"company":"Kerry Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"IRELAND","productType":"Dietary Supplement","year":"2017","type":"Inapplicable","leadProduct":"D-Chiroinositol","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Kerry Group","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Kerry Group \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Kerry Group \/ Undisclosed"},{"orgOrder":0,"company":"Instituto Nacional de Salud Publica, Mexico","sponsor":"Laboratorios de Biologicos y Reactivos de M\u00e9xico","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"MEXICO","productType":"Vaccine","year":"2012","type":"Inapplicable","leadProduct":"Seasonal Influenza Vaccine","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Instituto Nacional de Salud Publica, Mexico","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Instituto Nacional de Salud Publica, Mexico \/ Laboratorios de Biologicos y Reactivos de M\u00e9xico","highestDevelopmentStatusID":"9","companyTruncated":"Instituto Nacional de Salud Publica, Mexico \/ Laboratorios de Biologicos y Reactivos de M\u00e9xico"},{"orgOrder":0,"company":"Jiangsu Hengrui Medicine","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"CHINA","productType":"Undisclosed","year":"2022","type":"Inapplicable","leadProduct":"SHR7280","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Jiangsu Hengrui Medicine","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Tablet","sponsorNew":"Jiangsu Hengrui Medicine \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Jiangsu Hengrui Medicine \/ Undisclosed"},{"orgOrder":0,"company":"Physician Recommended Nutriceuticals","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Obstetrics\/Gynecology (Women\u2019s Health)","country":"U.S.A","productType":"Undisclosed","year":"2015","type":"Inapplicable","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Obstetrics\/Gynecology (Women\u2019s Health)","graph2":"Phase II\/ Phase III","graph3":"Physician Recommended Nutriceuticals","amount2":0,"highestDevelopmentShortName":"Ph II\/III","therapeuticAreaShortName":"Gynecology\/Obstetrics","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Physician Recommended Nutriceuticals \/ Undisclosed","highestDevelopmentStatusID":"9","companyTruncated":"Physician Recommended Nutriceuticals \/ Undisclosed"}]

    Find Clinical Drug Development Pipelines & Deals | PipelineProspector

    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Jiangsu Hengrui Medicine

                            China arrow
                            AAPS
                            Not Confirmed

                            Jiangsu Hengrui Medicine

                            China arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : SHR7280

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Phase II/III Study of Efficacy and Safety of SHR7280 Tablets in Subjects With Menorrhagia With Uterine Fibro...

                            Details : SHR7280 is a drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Leiomyoma-associated with Menorrhagia.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 05, 2022

                            Lead Product(s) : SHR7280

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            National Taiwan University Hospital

                            Country arrow
                            AAPS
                            Not Confirmed

                            National Taiwan University Hospital

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : TCM Biotech International Corp.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Radiation Cystitis Treated With Pentosan Polysulfate Sodium Trial

                            Details : Pentosan Polysulfate Sodium is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Cystitis.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            February 18, 2022

                            Lead Product(s) : Pentosan Polysulfate Sodium

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : TCM Biotech International Corp.

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eastern Virginia Medical School

                            Country arrow
                            AAPS
                            Not Confirmed

                            Eastern Virginia Medical School

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Progesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Watson Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vaginal Progesterone Supplementation in Women With PCOS Undergoing Ovulation Induction With Letrozole

                            Details : Progesterone is a Hormone drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Polycystic Ovary Syndrome.

                            Product Name : Undisclosed

                            Product Type : Hormone

                            Upfront Cash : Inapplicable

                            February 22, 2018

                            Lead Product(s) : Progesterone

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Watson Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kerry Group

                            Country arrow
                            AAPS
                            Not Confirmed

                            Kerry Group

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : D-Chiroinositol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Evaluation of the Mixture Myoinositol:D-chiro-inositol 3.6:1 in Women With Polycystic Ovary Syndrome

                            Details : D-Chiroinositol is a Dietary Supplement drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Polycystic Ovary Syndrome.

                            Product Name : Undisclosed

                            Product Type : Dietary Supplement

                            Upfront Cash : Inapplicable

                            June 28, 2017

                            Lead Product(s) : D-Chiroinositol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Centre For International Health

                            Country arrow
                            AAPS
                            Not Confirmed

                            Centre For International Health

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Vitamin B12

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Tribhuvan University Teaching Hospital, Institute of Medicine | NORCE Norwegian Research Centre AS | Sykehuset Innlandet HF

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Vitamin B12 Supplementation During Pregnancy on Cognitive Development

                            Details : Cobalamin is a Vitamins/Minerals/Inorganic Salts drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy.

                            Product Name : Undisclosed

                            Product Type : Vitamins/Minerals/Inorganic Salts

                            Upfront Cash : Inapplicable

                            March 07, 2017

                            Lead Product(s) : Vitamin B12

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Tribhuvan University Teaching Hospital, Institute of Medicine | NORCE Norwegian Research Centre AS | Sykehuset Innlandet HF

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            06

                            AMAG Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed

                            AMAG Pharmaceuticals

                            U.S.A arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Digoxin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Study of the Efficacy and Safety of AMAG-423 (Digoxin Immune Fab) in Antepartum Subjects With Severe Preeclamp...

                            Details : Digoxin is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pre-Eclampsia.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            January 02, 2017

                            Lead Product(s) : Digoxin

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            07

                            Physician Recommended Nutriceuticals

                            Country arrow
                            AAPS
                            Not Confirmed

                            Physician Recommended Nutriceuticals

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            A Study To Investigate The Effect Of A Natural Dietary Supplement On Peri-Menopausal Symptoms

                            Details : This drug candidate is currently being evaluated in phase II/ phase III clinical studies for the treatment of Menopause.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Inapplicable

                            July 14, 2015

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            08

                            Gynuity Health Projects

                            Country arrow
                            AAPS
                            Not Confirmed

                            Gynuity Health Projects

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Misoprostol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Effectiveness of Two Regimens of Misoprostol Alone for Early Pregnancy Termination and Use of SQPT for At-Home...

                            Details : Misoprostol is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Pregnancy.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            November 24, 2014

                            Lead Product(s) : Misoprostol

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            09

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            AAPS
                            Not Confirmed

                            Academisch Medisch Centrum - Universiteit van Amsterdam

                            Country arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            The Dutch STRIDER (Sildenafil TheRapy In Dismal Prognosis Early-onset Fetal Growth Restriction)

                            Details : Sildenafil is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Fetal Growth Retardation.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 28, 2014

                            Lead Product(s) : Sildenafil Citrate

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : ZonMw

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            10

                            Andromaco

                            Chile arrow
                            AAPS
                            Not Confirmed

                            Andromaco

                            Chile arrow
                            AAPS
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Study Phase : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Assessment of a Vaginal Ring With Meloxicam in the Treatment of Dysmenorrhea

                            Details : Meloxicam is a Other Small Molecule drug candidate, which is currently being evaluated in phase II/ phase III clinical studies for the treatment of Dysmenorrhea.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 02, 2014

                            Lead Product(s) : Meloxicam

                            Therapeutic Area : Obstetrics/Gynecology (Women’s Health)

                            Highest Development Status : Phase II/ Phase III

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth